Key result
Aspirin combination treatment for coronary heart disease is the subject of this systematic review and meta-analysis protocol, which currently reports no clinical findings.
Why the study?
Aspirin alone is reportedly less effective as a first-line treatment for coronary heart disease.
Meta-Analysis
Answers are grounded in this paper and cite their sources.
No practice change from protocol alone; leaves open optimal aspirin combinations in CHD pending completed synthesis.
BACKGROUND: Coronary heart disease (CHD) has a high incidence rate as a cardiovascular condition, primarily affecting the elderly and middle-aged individuals. CHD has debilitating effects on the standard of life of the elderly, and affecting their physical and psychological health. Reportedly, using aspirin alone is less effective as a first line of treatment for CHD. Therefore, this systematic review and meta-analysis will synthesize evidence on the effectiveness and safeness of aspirin combination treatment in treating patients with CHD. METHODS: A comprehensive meta-analysis is to be performed to evaluate the effectiveness and safety of aspirin combination treatment for CHD patients. A search will be performed on PubMed, EMBASE, Cochrane Central, WanFang, and Chinese National Knowledge Infrastructure till December 25, 2021 to identify randomized controlled trials, assess all related studies on the aspirin combination treatment in treating patients with CHD. In this systematic review, we will adopt the second version of Cochrane risk of bias assessment tool to assess the bias risk in all studies that fulfil the eligibility conditions. Two authors will separately conduct the study selection process, risk of bias assessment, and data extraction. Moreover, a random-effects meta-analysis will be conducted to synthesize evidence for all outcomes. Provided there is sufficient homogeneity among the studies, we will perform meta-analysis. I2 test will be employed to assess the heterogeneity of the outcomes. OSF REGISTRATION NUMBER: 10.17605/OSF.IO/MDTCA.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted a meta-analysis in Coronary heart disease. Aspirin combination treatment vs. Aspirin alone, other treatment, or no intervention was evaluated on All-cause mortality, vascular deaths, response rate, incidence of adverse reactions, cerebrovascular events, and non-fatal events. Aspirin combination treatment for coronary heart disease is the subject of this systematic review and meta-analysis protocol, which currently reports no clinical findings.
Synapse has enriched 10 related papers. Consider them for comparative context: